# Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer

> **NCT00004870** · PHASE1,PHASE2 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio**

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** oblimersen sodium
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00004870
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2002-09
- **Final completion:** 2002-09
- **Target enrollment:** — (—)
- **Last updated:** 2013-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004870, "Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00004870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*